Friday, January 21 2005

	ETHICS WORKSHOP
		Balancing Donor Risk and Recipient Outcome	David Cronin, MD, PhD \| Transcription \| View
		Case For Payments for Organs	Arthur Matas, MD \| Transcription \| View
		Case Against Payments for Organs	Arthur Caplan, PhD \| Transcription \| View
		Stewardship: Advocate for Greatest Good	Sandy Feng, MD, PhD \| Transcription \| View
		Stewardship: Advocate for Your Patient	Richard Freeman, MD \| Transcription \| View
		Surrogate Consent	Peter Angelos, MD, PhD \| Transcription \| View

	WHEN IS LESS REALLY MORE?
		Antibody Preconditioning with Minimal Post-Transplant Immunosuppression	Ron Shapiro, MD \| Transcription \| View
		The Role of Antilymphocyte Antibody Induction in Liver Transplantation	James Eason, MD \| Transcription \| View
		Steroid Avoidance Protocols in Pancreas Transplantation	Dixon Kaufman, MD, PhD \| Transcription \| View
		Homeostatic Repopulation of Lymphocytes Following Depletional Therapy	Thomas Mueller, MD \| Transcription \| View
		Successful Steroid Avoidance with Extended Daclizumab Induction	Minnie Sarwal, MD \| Transcription \| View
		Impact of Immunosupression on T Regulatory Cells	Douglas Hale, MD \| Transcription \| View

	KEYNOTE SPEAKER
		Clinical Transplantation: Unmet Needs and Opportunities for Science	Philip Halloran, MD \| Transcription \| View

	WHEN SCIENCE & ART FAIL, WHAT THEN?
		Acute Rejection vs Recurrent Hepatitis C: A Diagnostic & Management Dilemma	Sandy Feng, MD, PhD \| Transcription \| View
		Renal Insufficiency After Non-Renal Transplantation	John Magee, MD \| Transcription \| View
		Should Maintenance Immunosuppression Be Changed After a Diagnosis of Acute or Chronic Rejection?	Arthur Matas, MD \| Transcription \| View

	STANDARDS FOR TRANSPLANTATION: WHERE ARE WE & WHERE ARE WE GOING?
		HRSA / DOT	Ginny McBride \| Transcription \| View
		CMS	Barry Straube, MD \| Transcription \| View
		AOPO	Joseph Roth \| Transcription \| View
		UNOS	Robert Metzger, MD \| Transcription \| View
		ASTS	Peter Stock, MD, PhD \| Transcription \| View

Saturday, January 22 2005

	NON-TRADITIONAL REJECTION: TOO LITTLE ART OR TOO LITTLE SCIENCE?
		"Evil Humors" After Solid Organ Transplantation	Michael Fishbein, MD \| Transcription \| View
		The Armamentarium Against Acute Humoral Rejection	Robert Montgomery, MD, DPhil \| Transcription \| View
		NK Cells: The Third Pathway of Cardiac Allograft Vasculopathy	Joren Madsen, MD, DPhil \| Transcription \| View
		A Humoral Contribution to Chronic Rejection	Paul Terasaki, PhD \| Transcription \| View
		The Roll of TOR Inhibition in Chronic Cardiac Allograft Vasculopathy	Niloo Edwards, MD \| Transcription \| View

	PLENARY SESSION OF SELECTED ABSTRACTS
		Poly (ADP) Ribose Synthetase Inhibition in a Rodent Model of Heart Transplantation	Alex Farivar \| Transcription \| View
		The Effect of Immunosppression on Renal Function & Graft Histology	Patrick Dean \| Transcription \| View
		Achieving Desensitization & Preventing Humoral Rejection in Positive	Mark Stegall \| Transcription \| View
		Immunosuppression-Related Complications in 26 Patients with Type-1 Diabetes	Muhammad Hafiz \| Transcription \| View
		A Randomized Trial for Tacrolimus & Steroids vs Tacrolimus & Basiliximab	Marco Spada \| Transcription \| View
		The Pittsburgh Tolerance Protocol & Intestinal Transplantation	Kareem Abu-Elmagd \| Transcription \| View

	IMMUNOLOGIC PROFILING: CAN SCIENCE GUIDE ART?
		Beyond Genomics, How Proteomics & Metabolomics can be Used to Monitor the Graft	Peter Nickerson, MD \| Transcription \| View
		Clinical Utility of the ELISPOT Assay in Organ Transplantation	Donald Hricik, MD \| Transcription \| View
		A Real Time Portrait of Renal Allografts	Manikkam Suthanthriam, MD \| Transcription \| View
		BK Virema: A Barometer of Immunosppression	Daniel Brennan, MD \| Transcription \| View

Sunday, January 23 2005

	WHAT'S IN THE PIPELINE?
		The Pathways Less Taken	Jonathan Bromberg, MD, PhD \| Transcription \| View
		Costimulation Blockade with LEA29Y	Nancy Krieger, MD \| Transcription \| View
		Therapeutic Targeting of the CD40/CD154 Pathway in Transplantation	Christian Larsen, MD, PhD \| Transcription \| View
		Does Siplizumab/MEDI-507, an Anti-CD2 Monoclonal Antibody Have a Roll in Transplantation?	Benedict Cosimi, MD \| Transcription \| View
		FK 778 & Other Fujisawa Development Initiatives	Roy First, MD \| Transcription \| View
		Polyclonal ATG (Thymoglobulin) - Novel Mechansims from Nature's Combination Therapy	Gary Chan, PharmD \| Transcription \| View

	NEW TWISTS ON OLD DRUGS
		CNI: Old Dog New Tricks	Michael Mulligan, MD \| Transcription \| View
		TOR Inhibition: The Good & The Bad	Abhinav Humar, MD \| Transcription \| View

	DEBATES
		Protocols vs Gestalt
		Argument for Protocols	Robert Merion, MD \| Transcription \| View
		Argument for Gestalt	Herwig-Ulf Meier-Kriesche, MD \| Transcription \| View
		Rebuttle	Robert Merion, MD \| Transcription \| View
		Rebuttle	Herwig-Ulf Meier-Kriesche, MD \| Transcription \| View
		Question & Answer Session	Transcription \| View

		To Induce or To Not Induce
		Argument to Induce	James Allan, MD \| Transcription \| View
		Argument against Induction	R Duane Davis, MD \| Transcription \| View
		Rebuttle	James Allan, MD \| Transcription \| View
		Rebuttle	R Duane Davis, MD \| Transcription \| View
		Question & Answer Session	Transcription \| View

		Innovate at What price? Minimization vs Graft Loss
		Argument for Graft Loss	Flavio Vincenti, MD \| Transcription \| View
		Argument for Minimization	Allan Kirk, MD, PhD \| Transcription \| View
		Rebuttle	Flavio Vincenti, MD \| Transcription \| View
		Rebuttle	Allan Kirk, MD, PhD \| Transcription \| View
		Question & Answer Session	Transcription \| View